-
The total output value of the biological manufacturing industry in the Chengdu High-tech Zone has increased by more than 14%
Time of Update: 2021-12-07
For example, on November 5, Shamrock Bio was officially listed on the main board of the Stock Exchange of Hong Kong Limited, marking that Chengdu’s listed companies in the field of biomedicine have added "new faces"; on November 3, Yuanda Shuyang Pharmaceutical Human Fibrinogen The product has obtained the drug registration certificate issued by the National Medical Products Administration.
-
New medicine for cystic fibrosis!
Time of Update: 2021-12-07
Vertex Pharmaceuticals recently announced that the European Medicines Agency (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive review suggesting the approval of Kaftrio (ivacaftor/tezacaftor/elexacaftor) and ivacaftor combination drug regimen label expansion for treatment All CF patients aged 6 to 11 years with at least one F508del mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene .
-
2021 annual performance forecast: Chutian Technology, Dongfulong and other stocks are expected to increase
Time of Update: 2021-12-07
As of November 17, 2021, within 6 months, a total of one institution, China Securities Construction Investment, has made a prediction on Tailin Bio's 2021 annual performance; forecast 2021 net profit is 0.
-
The market is fully liberalized, and a large number of traditional Chinese medicine companies are stepping up their deployment in the field of traditional Chinese medicine formula particles
Time of Update: 2021-12-07
Currently, Shenwei Pharmaceutical has invested more than 1 billion yuan in research on the preparation process and quality standards, pharmacodynamics and clinical application of Chinese medicine formula granules, and has achieved significant results .
-
The API industry welcomes favorable policies, or accelerates the innovation and upgrading of the pharmaceutical equipment industry
Time of Update: 2021-12-07
With the advancement of centralized procurement policies, consistency evaluation, and drug-related approvals, as well as the impact of factors such as global order transfers, the scale of China's API
-
Changes in the chairman of two well-known pharmaceutical companies
Time of Update: 2021-12-07
In addition, under the influence of national policies, the pharmaceutical distribution industry has become more competitive in the industry, leading companies have obvious advantages, and the rise of new business forms such as Internet hospitals is also an important factor affecting its development .
-
Opportunities in these fields have come after the collection
Time of Update: 2021-12-07
The trend of low-level competition will be terminated, which is also in line with the global development trend of the pharmaceutical industry-gradually concentrated, and small and medium-sized enterprises without innovative capabilities will be eliminated .
-
Pien Tze Huang Apixaban tablets received drug registration certificate to prevent venous thromboembolism
Time of Update: 2021-12-07
On November 15, Pien Tze Huang issued an announcement stating that the company's Apixaban tablets received the "Drug Registration Certificate" approved and issued by NMPA . Apixaban is a new oral ant
-
The epilepsy drug market may break the 6 billion mark, and pharmaceutical companies compete for the first imitation of sodium valproate oral solution
Time of Update: 2021-12-07
With the production of Sichuan Baojiantang Sodium Valproate Oral Solution, the field of antiepileptic drugs may usher in new competitors .
In the field of sodium valproate injection, companies applying for consistency evaluation include Fu'an Pharmaceutical, Xi'an Yuanda Detian Pharmaceutical, Hebei Renheyikang, and Sichuan Creed Pharmaceuticals .
-
"Paste health preservation" has become the theme of winter tonic, and the equipment behind it should not be underestimated
Time of Update: 2021-12-07
In recent years, in the face of increasing patient demand and the rapid development of modern technology, the application and innovation of ointment are in the ascendant, the process standards and requirements are continuously improved, the production is more and more exquisite, the processing requirements are more and more refined, and the equipment is also more and more refined.
-
Osaikang Pharmaceutical's third-generation EGFR-TKI new drug listing application accepted
Time of Update: 2021-12-07
Epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) is an earlier developed targeted drug for the treatment of NSCLC and has undergone three generations of product evolution .
In addition, Osaikang Pharmaceutical is also developing Class 1 new drugs for the treatment of NSCLC with Exon14 mutations and third-generation EGFR inhibitor resistance .
-
CAR-T therapy has huge market development space, which is attracting domestic pharmaceutical companies to actively explore
Time of Update: 2021-12-07
It is worth noting that, facing the considerable market prospects, pharmaceutical companies have begun to accelerate their exploration in the field of CAR-T cell therapy .
But in fact, domestic pharmaceutical companies have been actively deploying CAR-T cell therapy drugs in recent years .
-
Domestic reflux esophagitis drugs "first imitation battle" adds new members
Time of Update: 2021-12-07
It is understood that the launch of voronola fumarate green tablets provides a new treatment option for patients with reflux esophagitis .
In terms of generic drugs, on November 15th, Kelun Pharmaceutical reported Takeda Original Research's voronola fumarate green tablets for generic 4 types and was accepted (acceptance number CYHS2102022, CYHS2102023) .
-
Announcement of the clinical data of the new conjugation drug VDC!
Time of Update: 2021-12-07
AU-011's dual mechanism of killing tumors (Source: Aura official website)The Phase Ib/II clinical trial of AU-011 evaluated the safety and effectiveness of IVT administration in the treatment of IL and CM .
-
The new domestic hypoglycemic medicine is hot! Over 50 Class 1 new drugs hit Hengrui and other 3 major tracks
Time of Update: 2021-12-07
Including compound preparations, there are currently 9 domestic GLP-1 receptor agonists approved for marketing (2 are domestically produced Class 1 new drugs).
In addition to the two domestically-made GLP-1 receptor agonists that have been approved for marketing, according to incomplete statistics, there are currently 17 domestically-made Class 1 new drugs in phase I and above .
-
The scale of the Chinese medicine market continues to expand, and high-quality development becomes the top priority of pharmaceutical companies
Time of Update: 2021-12-07
According to this trend, the industry predicts that the market size of China's traditional Chinese medicine industry will maintain a compound annual growth rate of about 14% in the next few years.
-
The number of entrants in the Chinese medicine formula granule market is increasing, and the market war is about to start
Time of Update: 2021-12-07
The project is expected to produce 1,049 tons of decoction pieces and formula granules of various types of Chinese medicine in the first year of production, with an output value of 238 million yuan.
-
Accelerate the substitution of original research drugs, local pharmaceutical companies are constantly making efforts
Time of Update: 2021-12-07
At present, with the continuous efforts of local pharmaceutical companies, domestic high-end generic drugs are accelerating the replacement of the original research drug market position .
-
Deck Pharmaceuticals announced the positive preclinical data of two drugs during the SITC annual meeting on November 12
Time of Update: 2021-12-07
At the same time, it is further analyzed by quantitative system pharmacological model Supported the dose selection strategy for the drug-Preclinical data of ERK1/2 inhibitor ATG-017 combination therapy supports future clinical developmentShanghai and Hong Kong November 15, 2021/PRNewswire/ - Deqi Pharmaceutical Co.
-
The State Food and Drug Administration cancels the registration certificates of 8 varieties of drugs including Xiaoerfenaminokamin granules
Time of Update: 2021-12-07
After evaluation, the State Drug Administration has decided to stop the production, sales and use of the above-mentioned eight varieties in China and cancel the drug registration certificate from now on .
